{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiesyyoumk53v72nhjz6dulw2seovpsy4vxmw747hm3svosq5vhrga",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mel3sfz72cp2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibuadvpy6itsd2avfqwypovuelf7sxicj7plqartndfpb275bfzci"
    },
    "mimeType": "image/jpeg",
    "size": 79865
  },
  "path": "/2026/02/10/nektar-therapeutics-rezpeg-eczema-drug-maintains-skin-response-study/?utm_campaign=rss",
  "publishedAt": "2026-02-10T12:00:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "Pharmaceuticals",
    "research",
    "STAT+"
  ],
  "textContent": "An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding investor expectations.",
  "title": "STAT+: Eczema drug from Nektar Therapeutics maintains skin responses in one-year study",
  "updatedAt": "2026-02-10T13:50:38.000Z"
}